Spectranetics Pursuing Narrower Critical Limb Ischemia Indication Via 510(k)
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics is seeking 510(k) clearance for treatment of totally occluded leg arteries with its CVX-300 excimer laser catheter following FDA's October rejection of a broader PMA supplement
You may also be interested in...
Spectranetics Takes CLiRpath To 510(k) Clearance For Leg Artery Occlusions
Spectranetics will support a U.S. clinical trial for expanded use of its CVX-300 excimer laser technology for heart attacks with incremental profits from CLiRpath leg artery occlusion treatment sales
Spectranetics Takes CLiRpath To 510(k) Clearance For Leg Artery Occlusions
Spectranetics will support a U.S. clinical trial for expanded use of its CVX-300 excimer laser technology for heart attacks with incremental profits from CLiRpath leg artery occlusion treatment sales
FDA Passes On Critical Limb Ischemia Laser; Spectranetics Ponders Options
Spectranetics hopes FDA will accept a retrospective analysis of bypass surgery data as a control arm to support a critical limb ischemia indication for its CVX-300 excimer laser catheter system in lieu of further clinical studies